Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Strata Skin Sciences's EBIT per Share for the
three
months ended in Dec. 2025 was €0.09.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.97.
During the past 3 years, the average EBIT per Share Growth Rate was 2.10% per year.
During the past 5 years, the average EBIT per Share Growth Rate was -1.50% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 27.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Strata Skin Sciences's EBIT per Share or its related term are showing as below:
FRA:E2O'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -44.6 Med: 8.9 Max: 73.9
Current: 2.1
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Strata Skin Sciences was 73.90% per year. The lowest was -44.60% per year. And the median was 8.90% per year.
FRA:E2O's 3-Year EBIT Growth Rate is ranked worse than 60.06% of 686
companies
in the Medical Devices & Instruments industry
Industry Median: 9.25
vs FRA:E2O: 2.10
Strata Skin Sciences (FRA:E2O) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Strata Skin Sciences EBIT per Share Related Terms
Strata Skin Sciences EBIT per Share Historical Data
* Premium members only.
The historical data trend for Strata Skin Sciences's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.97
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Strata Skin Sciences (FRA:E2O) has a EBIT per Share of €-0.97 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Strata Skin Sciences and its competitors. According to the industry distribution chart, Strata Skin Sciences ranks #412 out of 686 companies in the Medical Devices & Instruments industry, placing it in the top 60.1%.
Is Strata Skin Sciences' EBIT per Share too high?
Strata Skin Sciences' current EBIT per Share is €-0.97. Based on the distribution chart, Strata Skin Sciences ranks #412 out of 686 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Strata Skin Sciences has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does Strata Skin Sciences' EBIT per Share compare to ODYY and NUMD?
According to the Medical Devices & Instruments industry distribution chart, Strata Skin Sciences ranks #412 out of 686 companies for EBIT per Share. This places Strata Skin Sciences in the lower half of its industry. The industry median EBIT per Share is 9.25. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Devices & Instruments company?
The median EBIT per Share among Medical Devices & Instruments companies is 9.25, based on 686 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Strata Skin Sciences and its competitors. For the Medical Devices & Instruments industry, the median EBIT per Share is 9.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Strata Skin Sciences's current EBIT per Share is €-0.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Strata Skin Sciences stock overvalued right now?
Strata Skin Sciences (FRA:E2O) has a current EBIT per Share of €-0.97. The stock's GF Value™ is €19,176.00, compared to a current price of €3.76 — trading 100% below its estimated fair value. The current EBIT per Share is €-0.97. Strata Skin Sciences' overall GF Score™ is 38/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Strata Skin Sciences (FRA:E2O), the current EBIT per Share is €-0.97 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Strata Skin Sciences (FRA:E2O) Overvalued in 2026?
Based on GuruFocus' analysis, Strata Skin Sciences stock appears to be undervalued.
The current stock price of €3.76 is trading 100% below its estimated GF Value™ of €19,176.00.
Key valuation signals for FRA:E2O:
EBIT per Share: €-0.97
GF Value™: €19,176.00 vs. price of €3.76 (100% below fair value)
No single metric tells the full story. See the FRA:E2O stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Strata Skin Sciences Inc is a medical technology company engaged in developing and commercializing products for the treatment of dermatological disorders. Its primary products include the XTRAC excimer laser and VTRAC lamp systems utilized in the treatment of psoriasis, vitiligo, and various other skin conditions. Its operating segment includes Dermatology Recurring Procedures, which is the key revenue driver, and Dermatology Procedures Equipment. The Dermatology Recurring Procedures segment derives its revenues from the usage of its equipment by dermatologists to perform XTRAC procedures. Its Dermatology Procedures Equipment segment generates revenues from the sale of equipment, such as lasers and lamp products. Geographically, it derives a majority of revenue from the United States.
38GF Score
Get the complete analysis for FRA:E2O
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:E2O has been successfully added to your 
